Predictive oncology stock.

Here are just a few of the top artificial intelligence (AI) stocks to buy and hold today.Predictive Oncology (): The company could be a game-changer in cancer drug development. C3.ai (): After a ...

Predictive oncology stock. Things To Know About Predictive oncology stock.

The average Predictive Oncology stock forecast 2023 represents a 0.36% increase from the last price of $3.08999991416931. For Predictive Oncology stock forecast for 2024, 12 predictions are offered for each month of 2024 with average Predictive Oncology stock forecast of $3.76, a high forecast of $5.03, and a low …Mar 9, 2023 · EAGAN, Minn., March 09, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI) , a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities ... Predictive Oncology Inc. 91 43rd Street. Suite 110. Pittsburgh, Pennsylvania 15201. Phone 1 412 432-15000. Industry Medical Equipment/Supplies. Sector Health Care/Life Sciences. Predictive Oncology Inc. is focused on applying artificial intelligence to personalized medicine and drug discovery. Its operating business unit consists of Helomics, TumorGenesis and Skyline Medical. Predictive Oncology Inc., formerly known as Precision Therapeutics Inc., is based in MINNEAPOLIS. Stock Name. Country.Institutional investors purchased a net $136.9 thousand shares of POAI during the quarter ended March 2019, and now own 9.41% of the total float, a percentage ...

IDAI Vs POAI: Stock comparison by Artificial Intelligence. Which is a better buy? Make smart data-driven investment decisions and get unique insights. Start now and save 50% for the first 3 months save 50% for the first 3 months. Ticker. Company. Your search produced no matches. We currently support US stocks and STOXX Europe 600 …

Predictive Oncology : If you can look past a reverse stock split, POAI stock is one worth watching. Rekor Systems ( REKR ): The company has a first-mover advantage in a sector that has the ...

The estimated Net Worth of J Melville Engle is at least $60 Thousand dollars as of 24 May 2022. Mr Engle owns over 159,500 units of Predictive Oncology stock worth over $56,950 and over the last 14 years he sold POAI stock worth over $0. In addition, he makes $3,000 as Chairman & CEO at Predictive Oncology.Amesite Inc. (NASDAQ:AMST) posted its earnings results on Monday, November, 13th. The company reported ($0.35) EPS for the quarter. The company earned $0.06 million during the quarter. Amesite had a negative trailing twelve-month return on equity of 52.99% and a negative net margin of 552.07%.May 16, 2022 · Predictive Oncology Inc. EAGAN, Minn., May 16, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (Nasdaq: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused ... According to CBS News, Harry Dent’s predictions in his books have never been right. His most accurate prediction was from his 1993 book; he predicted that the stock market would rise substantially, but he was a year early with his predictio...Apr 20, 2023 · Common Stock Will Begin Trading on Split-Adjusted Basis on April 24, 2023. EAGAN, Minn., April 20, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or the “Company”), today announced that it is effecting a reverse stock split of its common stock at a ratio of 1 post-split share for every 20 pre ...

Daniel Handley POAI stock SEC Form 4 insiders trading. Daniel has made over 4 trades of the Predictive Oncology stock since 2022, according to the Form 4 filled with the SEC. Most recently he bought 6,000 units of POAI stock worth $2,460 on 15 December 20226,000 units of POAI stock worth $2,460 on 15 December 2022

Predictive Oncology Inc (POAI) stock is trading at $0.29 as of 2:08 PM on Friday, Mar 31, a gain of $0.01, or 3.39% from the previous closing price of $0.28. The stock has traded between $0.28 and $0.30 so far today. Volume today is below average. So far 218,615 shares have traded compared to average volume of 340,765 shares.

Mar 22, 2023 · Effective March 16, 2023, Predictive Oncology and Cancer Research Horizons, the world’s largest private funder of cancer research, have partnered to drive the development of oncology drugs utilizing Predictive Oncology’s PEDAL platform that pairs artificial intelligence (AI) with the world’s largest biobank of tumor samples; Nov 8, 2023 · PITTSBURGH, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, announced today that it has completed a multi-year study ... Effective March 16, 2023, Predictive Oncology and Cancer Research Horizons, the world’s largest private funder of cancer research, have partnered to drive the development of oncology drugs utilizing Predictive Oncology’s PEDAL platform that pairs artificial intelligence (AI) with the world’s largest biobank of tumor samples;Predictive Oncology Inc (NASDAQ: POAI) shares are trading lower by 15.81% to $0.23 Friday morning after the company announced a reverse stock split. What Else? Per an SEC filing, the reverse stock ...Aug 11, 2022 · An increase of cash and equivalents from $25 million on March 31, 2022, to $28 million at quarter end, which represents a positive change of 12%. Q2 2022 financial results. Predictive Oncology’s ... PITTSBURGH, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, announced today that it has completed a multi-year study with UPMC Magee-Womens Hospital. The objective of the study was to evaluate the use of AI to build multi-omic machine learning (ML) models …The estimated Net Worth of J Melville Engle is at least $86.4 Tisíc dollars as of 24 May 2022. Mr Engle owns over 159,500 units of Predictive Oncology stock worth over $83,391 and over the last 14 years he sold POAI stock worth over $0. In addition, he makes $3,000 as Chairman & CEO at Predictive Oncology.

The Price to Sales ratio or P/S is calculated as price divided by sales. After the P/E ratio, it's one of the most common valuation metrics. If the P/S ratio is 1, that means you're paying $1 for ...finance.yahoo.com - March 21 at 3:52 PM. Predictive Oncology Inc.: Predictive Oncology Announces Distribution of Series F Preferred Stock to Holders of its Common Stock. finanznachrichten.de - March 17 at 10:22 AM. Predictive Oncology and Cancer Research Horizons partner up to pursue development of cancer drugs.Get the latest Oncology Pharma Inc (ONPH) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.Predictive Oncology, Inc. engages in the application of artificial intelligence medicine business and provision of cleared STREAMWAY System for automated, direct-to-drain medical fluid disposal, and associated products. It operates through the following segments: Helomics, zPREDICTA, Skyline, Soluble, and Corporate.The first split for POAI took place on October 29, 2019. This was a 1 for 10 reverse split, meaning for each 10 shares of POAI owned pre-split, the shareholder ...The estimated Net Worth of Carl I. Schwartz is at least $10.3 Million dollars as of 22 October 2020. Dr Schwartz owns over 640 units of Predictive Oncology stock worth over $9,893,634 and over the last 7 years he sold POAI stock worth over $544. In addition, he makes $433,000 as CEO & Director at Predictive Oncology.

Daniel Handley POAI stock SEC Form 4 insiders trading. Daniel has made over 4 trades of the Predictive Oncology stock since 2022, according to the Form 4 filled with the SEC. Most recently he bought 6,000 units of POAI stock worth $2,460 on 15 December 20226,000 units of POAI stock worth $2,460 on 15 December 2022He oversees Predictive Oncology’s solubility and stability contracts for numerous pharmaceutical/biotech companies. From 1981 to 2016, Dr. DeLucas was a faculty member at the University of Alabama at Birmingham (UAB) where he served as a Professor in the School of Optometry, Senior Scientist and Director of the Comprehensive Cancer Center X ...

Mar 9, 2023 · Predictive Oncology Inc. EAGAN, Minn., March 09, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI) , a science-driven company leveraging its proprietary artificial intelligence and ... May 26, 2023 · Predictive Oncology (NASDAQ: POAI) is an early-stage AI pharma stock with a differentiated business model. The company owns a biorepository of tumor samples, a lab and a good manufacturing ... Nov 13, 2023 · POAI U.S.: Nasdaq Predictive Oncology Inc. Watch list NEW Set a price target alert Premarket Last Updated: Oct 27, 2023 7:12 a.m. EDT Delayed quote $ 2.8800 0.02 0.70% Before Hours Volume: 35... Aug 11, 2022 · An increase of cash and equivalents from $25 million on March 31, 2022, to $28 million at quarter end, which represents a positive change of 12%. Q2 2022 financial results. Predictive Oncology’s ... Predictive Oncology Inc (POAI) stock is trading at $5.48 as of 10:17 AM on Thursday, Jun 29, a rise of $0.35, or 6.82% from the previous closing price of $5.13. The stock has traded between $5.36 and $5.79 so far today. Volume today is 132,703 compared to average volume of 171,018. More About Predictive Oncology IncBased on 79,403,893 shares of common stock issued and outstanding as of March 17, 2023, immediately following the Reverse Stock Split, the Company would have approximately 39,701,947 shares of common stock issued and outstanding (without giving effect to rounding for fractional shares) if the ratio for the Reverse Stock Split is one-for- …What's Thomas Goldrick's mailing address? Thomas's mailing address filed with the SEC is 2915 COMMERS DRIVE, SUITE 900, , EAGAN, MN, 55121.

Predictive Oncology Inc stock performance at a glance. Check Predictive Oncology Inc’s past financial performance, like revenue or net income, plus the top level summary of its past and current market value.

Discover historical prices for POAI stock on Yahoo Finance. View daily, weekly or monthly format back to when Predictive Oncology Inc. stock was issued.

Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Helomics, zPREDICTA, Soluble and Skyline. It derives prime revenue from the Skyline segment which consists of the STREAMWAY System product sales, and TumorGenesis subsidiary (Research and Development) is included within corporate. The STREAMWAY System ... Nov 27, 2023 · The Price to Sales ratio or P/S is calculated as price divided by sales. After the P/E ratio, it's one of the most common valuation metrics. If the P/S ratio is 1, that means you're paying $1 for ... The NFL’s preseason’s about to start, and that means regular season games will be kicking off before we know it. And since we all love to predict the future way before it really makes sense to do so, it feels like a great time to take stock...Find the latest Predictive Oncology Inc (POAI) discussion and analysis from iHub's community of investors.Cardiff Oncology is a prime takeover target heading into 2022. The pharmaceutical industry appears poised for a record-breaking level of merger and acquisition (M&A) activity in 2022. Four ...PITTSBURGH, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, announced today …Predictive Oncology share price went down by -20.96% last month. The next quarterly earnings date for Predictive Oncology is scheduled on November 15, 2023. Predictive Oncology's next ex-dividend date is November 15, 2023.The shares of common stock described above (but not the warrants or the shares of common stock underlying the warrants) were offered by the Company in the registered direct offerings pursuant to ...

By Chris Markoch, InvestorPlace Contributor Aug 16, 2023, 5:11 pm EST. Finding little-known AI stocks may be critical to unearthing the true opportunity in AI. Predictive Oncology ( POAI ): Offers ...Predictive Oncology CEO Raymond Vennare and Cvergenx CEO Javier Torres-Roca join Natalie Stoberman to share news of their new partnership to develop the first-ever genomics-based approach to precis...Apr 24, 2023 · Common Stock Will Begin Trading on Split-Adjusted Basis on April 24, 2023. EAGAN, Minn., April 20, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or the “Company”), today announced that it is effecting a reverse stock split of its common stock at a ratio of 1 post-split share for every 20 pre ... Real-time quotes, advanced visualizations, historical statements, and much more. Selling, General and Administrative Excl. Other. POAI - Predictive Oncology Inc - Stock screener for investors and traders, financial visualizations. Instagram:https://instagram. demo day trading appst engineering ltdtop futures traderslvmh sotck Buying Predictive Oncology Inc stock carries the risk of losing money if the stock price goes down. However, the stock also has the potential for significant returns if the price goes up. As with any investment, it’s crucial to conduct research and consider the overall market trends before deciding.Nov 14, 2023 · Predictive Oncology recorded revenue of $715,056 in the third quarter of 2023, compared to $455,827 for the comparable period in 2022. The increase in revenues related primarily to higher sales of ... haus etfmedical insurance companies in maryland Daniel Handley POAI stock SEC Form 4 insiders trading. Daniel has made over 4 trades of the Predictive Oncology stock since 2022, according to the Form 4 filled with the SEC. Most recently he bought 6,000 units of POAI stock worth $2,460 on 15 December 20226,000 units of POAI stock worth $2,460 on 15 December 2022ETFs positionnés sur Predictive Oncology Inc. Nom, Poids, Encours, Varia. 1 janv. Note Invest. VANGUARD TOTAL STOCK MARKET ... msft tipranks The Predictive Oncology stock forecast for tomorrow is $ 2.88, which would represent a -0.32% loss compared to the current price. In the next week, the price of POAI is expected to increase by 14.32% and hit $ 3.30. As far as the long-term Predictive Oncology stock forecast is concerned, here ... Effective March 16, 2023, Predictive Oncology and Cancer Research Horizons, the world’s largest private funder of cancer research, have partnered to drive the development of oncology drugs utilizing Predictive Oncology’s PEDAL platform that pairs artificial intelligence (AI) with the world’s largest biobank of tumor samples;